ImmunityBio, Inc. (IBRX) Posts Strong Preliminary Q1 Sales on ANKTIVA Momentum

We recently compiled a list of the 10 Best Mid Cap Stocks to Invest In According to Billionaires. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best mid cap stocks.

TheFly reported on April 9 that IBRX reported preliminary first-quarter 2026 net product revenue of about $44.2 million, exceeding the consensus estimate of $43.17 million. Its lead therapy, ANKTIVA, has secured approvals or authorizations across five regulatory regions, covering roughly 34 countries.

The company also confirmed that enrollment for its key BCG-naive CIS study has been completed, with the monitoring committee determining that no further participants are needed. A supplemental biologics license application remains planned for submission in 2026. As of March 31, 2026, ImmunityBio, Inc. (NASDAQ:IBRX) held approximately $380.9 million in cash, cash equivalents, and marketable securities. The company continues to focus on expanding its presence in the U.S. while increasing its reach across international markets.

ImmunityBio, Inc. (IBRX) Posts Strong Preliminary Q1 Sales on ANKTIVA Momentum

In a separate move, on April 6, IBRX responded to a communication from the FDA’s Office of Prescription Drug Promotion concerning issues identified on March 13 related to a podcast and a television advertisement. The company clarified that the advertisement referenced had never been broadcast and confirmed that the podcast content in question has been removed, with steps taken to eliminate it from external platforms. It also outlined corrective measures, including stricter internal review processes, enhanced compliance protocols, and additional oversight to ensure future promotional materials meet regulatory standards.

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company developing immunotherapies to treat cancer and infectious diseases. Its platform focuses on activating the immune system using novel cell and vaccine-based approaches to improve long-term patient outcomes.

While we acknowledge the risk and potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IBRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.